A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.
Body mass index
GLP-1 receptor agonist
exenatide
glucose metabolism
liver steatosis
metabolic syndrome
pediatric obesity
Journal
Pediatric obesity
ISSN: 2047-6310
Titre abrégé: Pediatr Obes
Pays: England
ID NLM: 101572033
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
05
04
2019
revised:
13
01
2020
accepted:
26
01
2020
pubmed:
18
2
2020
medline:
12
11
2020
entrez:
17
2
2020
Statut:
ppublish
Résumé
Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity. To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.
Sections du résumé
BACKGROUND
Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity.
OBJECTIVE
To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity.
METHODS
Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m
RESULTS
Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm
CONCLUSIONS
Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.
Substances chimiques
Anti-Obesity Agents
0
Exenatide
9P1872D4OL
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12624Informations de copyright
© 2020 The Authors. Pediatric Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
WHO | Facts and figures on childhood obesity. WHO. http://www.who.int/end-childhood-obesity/facts/en/. Accessed September 4, 2019.
Mead E, Brown T, Rees K, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years. Cochrane Database of Systematic Reviews. 2017;(6). doi:https://doi.org/10.1002/14651858.CD012651
Al-Khudairy L, Loveman E, Colquitt JL, et al. Diet, physical activity and behavioural interventions for the treatment of overweight or obese adolescents aged 12 to 17 years. Cochrane Database of Systematic Reviews. 2017;(6). doi:https://doi.org/10.1002/14651858.CD012691
Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92(2):251-265. https://doi.org/10.1016/j.mayocp.2016.09.017.
Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. https://doi.org/10.1136/bmj.d7771.
Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993;268(26):19650-19655.
Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936-944. https://doi.org/10.1111/jgh.13264.
Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity. And Stress Medical Science Monitor. 2005;11(8):271-278.
Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012;20(2):364-370. https://doi.org/10.1038/oby.2011.337.
Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr. 2013;167(4):355-360. https://doi.org/10.1001/jamapediatrics.2013.1045.
WHO | BMI-for-age (5-19 years). WHO. http://www.who.int/growthref/who2007_bmi_for_age/en/. Accessed March 6, 2018.
Flegal KM, Wei R, Ogden CL, Freedman DS, Johnson CL, Curtin LR. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. Am J Clin Nutr. 2009;90(5):1314-1320. https://doi.org/10.3945/ajcn.2009.28335.
Flegal KM, Cole TJ. Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts.-PubMed-NCBI. Natl Health Stat Report. 2013;11(63):1-3.
Becker W, Lyhne N, Pedersen AN, et al. Nordic Nutrition Recommendations 2004 - integrating nutrition and physical activity. Scandinavian Journal of Nutrition. 2004;48(4):178-187.
Braet C, O'Malley G, Weghuber D, et al. The assessment of eating behaviour in children who are obese: a psychological approach. A position paper from the European childhood obesity group. Obes Facts. 2014;7(3):153-164. https://doi.org/10.1159/000362391.
Plachta-Danielzik S, Landsberg B, Seiberl J, et al. Longitudinal data of the Kiel Obesity Prevention Study (KOPS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(6-7):885-891. https://doi.org/10.1007/s00103-012-1494-3.
Forslund A, Staaf J, Kullberg J, Ciba I, Dahlbom M, Bergsten P. Uppsala longitudinal study of childhood obesity: protocol description. Pediatrics. 2014;133(2):e386-e393. https://doi.org/10.1542/peds.2013-2143.
Staaf J, Labmayr V, Paulmichl K, et al. Pancreatic fat is associated with metabolic syndrome and visceral fat but not beta-cell function or body mass index in pediatric obesity. Pancreas. 2017;46(3):358-365. https://doi.org/10.1097/MPA.0000000000000771.
Berglund J, Kullberg J. Three-dimensional water/fat separation and T 2* estimation based on whole-image optimization-application in breathhold liver imaging at 1.5 T. Magnetic Resonance Medicine. 2012;67(6):1684-1693. https://doi.org/10.1002/mrm.23185.
Hamilton G, Yokoo T, Bydder M, et al. In vivo characterization of the liver fat 1H MR spectrum. NMR Biomed. 2011;24(7):784-790. https://doi.org/10.1002/nbm.1622.
Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395. https://doi.org/10.2337/dc12-2480.
Borm GF, Fransen J, Lemmens WAJG. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol. 2007;60(12):1234-1238. https://doi.org/10.1016/j.jclinepi.2007.02.006.
Middleton MS, Natta MLV, Heba ER, et al. Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology. 2018;67(3):858-872. https://doi.org/10.1002/hep.29596.
Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310. https://doi.org/10.1210/jc.2010-2081.
Mead E, Atkinson G, Richter B, et al. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database of Systematic Reviews. Ltd: John Wiley & Sons; 2016. https://doi.org/10.1002/14651858.CD012436.
Ryder JR, Kaizer AM, Jenkins TM, Kelly AS, Inge TH, Shaibi GQ. Heterogeneity in response to treatment of adolescents with severe obesity: the need for precision obesity medicine. Obesity. 2019;27(2):288-294. https://doi.org/10.1002/oby.22369.
Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7(1):27-43. https://doi.org/10.1007/s13300-016-0155-1.
Hagman E, Danielsson P, Brandt L, Ekbom A, Marcus C. Association between impaired fasting glycaemia in pediatric obesity and type 2 diabetes in young adulthood. Nutr Diabetes. 2016;6(8):e227. https://doi.org/10.1038/nutd.2016.34.
Patton HM, Lavine JE, Natta MLV, Schwimmer JB, Kleiner D, Molleston J. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology. 2008;135(6):1961-1971.e2. https://doi.org/10.1053/j.gastro.2008.08.050.
Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev. 2014;30(6):521-529. https://doi.org/10.1002/dmrr.2561.
Bizino MB, Jazet IM, de Heer P, et al. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia. 2020;63(1):65-74. https://doi.org/10.1007/s00125-019-05021-6.
Tomlinson B, Hu M, Zhang Y, Chan P, Liu Z-M. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs. 2016;25(10):1167-1179. https://doi.org/10.1080/13543784.2016.1221925.
Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. New England Journal of Medicine. 2019;381(7):637-646. https://doi.org/10.1056/NEJMoa1903822.
Christensen RM, Juhl CR, Torekov SS. Benefit-risk assessment of obesity drugs: focus on glucagon-like peptide-1 receptor agonists. Drug Saf. 2019;42(8):957-971. https://doi.org/10.1007/s40264-019-00812-7.